Bimekizumab in Psoriasis: 3-Year Outcomes
Investigators compare patient-reported symptoms and quality-of-life outcomes vs secukinumab.
-
By
-
Kathryn Wighton
-
March 12, 2026
-
Clinical Scorecard: Bimekizumab in Psoriasis: 3-Year Outcomes
At a Glance
| Category | Detail |
|---|
| Condition | Moderate to severe plaque psoriasis |
| Key Mechanisms | Bimekizumab targets IL-17A and IL-17F, leading to rapid symptom relief and improved quality of life. |
| Target Population | Adults with moderate to severe plaque psoriasis |
| Care Setting | Multicenter, randomized clinical trial |
Key Highlights
- Significant improvement in symptoms reported as early as week 4.
- At year 3, 62.2% of continuous bimekizumab patients achieved PASI 0 and DLQI 0 or 1.
- Bimekizumab showed higher rates of symptom resolution compared to secukinumab at multiple time points.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of psoriasis should be based on clinical evaluation and patient history.
Management
- Bimekizumab is recommended for patients with moderate to severe plaque psoriasis.
Monitoring & Follow-up
- Regular assessment of symptoms and quality of life using validated tools like PASI and DLQI.
Risks
- Consider potential treatment-related adverse events and lack of efficacy as reasons for discontinuation.
Patient & Prescribing Data
743 patients with moderate to severe plaque psoriasis
Bimekizumab administered at 320 mg every 4 weeks for 16 weeks, then every 8 weeks.
Clinical Best Practices
- Utilize patient-reported outcome measures to assess treatment effectiveness.
- Monitor for comorbid conditions that may affect treatment outcomes.
References
